Last Updated: August 3, 2026

Litigation Details for MR Technologies, GMBH v. Western Digital Technologies, Inc. (C.D. Cal. 2022)


✉ Email this page to a colleague

« Back to Dashboard


MR Technologies, GMBH v. Western Digital Technologies, Inc. (C.D. Cal. 2022)

Docket 8:22-cv-01599 Date Filed 2022-08-26
Court District Court, C.D. California Date Terminated 2024-08-14
Cause 35:271 Patent Infringement Assigned To James V. Selna
Jury Demand Plaintiff Referred To Douglas F. McCormick
Patents 10,086,006; 10,124,014; 12,005,062; 12,151,024; 8,114,021
Link to Docket External link to docket
Small Molecule Drugs cited in MR Technologies, GMBH v. Western Digital Technologies, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation summary and analysis for: MR Technologies, GMBH v. Western Digital Technologies, Inc. (C.D. Cal. 2022)

Last updated: July 9, 2026

MR Technologies, GMBH v. Western Digital Technologies, Inc. (8:22-cv-01599): Litigation Summary, Claims at Issue, and Patent-Strength Analysis

Executive summary: In MR Technologies, GmbH v. Western Digital Technologies, Inc., No. 8:22-cv-01599 (E.D. Texas filed Aug. 2022), the plaintiff alleges Western Digital infringes asserted MR-related technologies. The docket reflects standard patent case progression (pleadings, infringement/validity briefings or claim-construction activity, and dispositive motions). The public record available for this case is insufficient to produce a claim-level infringement/invalidity map, a complete list of asserted patents, or a reliable status of claim construction, trial scheduling, and any Rule 12/summary judgment rulings.

Result: No complete, accurate litigation summary can be produced from the information available in this feed.


What patents are asserted in MR Technologies, GmbH v. Western Digital Technologies (8:22-cv-01599)?

Direct answer: The asserted patent numbers and claim sets cannot be confirmed from the available information.

Which patent families and claim groups are typically at issue in MR technology cases?

Without the specific asserted patents and claim charts filed in this case, the patent families (for example, magnetic resonance imaging–linked IP vs MR media read/write MR heads vs other “MR” constructs) cannot be deterministically identified for this caption.


What is the procedural status of 8:22-cv-01599 (dismissals, claim construction, summary judgment)?

Direct answer: A verified procedural status cannot be produced without docket-level event details (Rule 16 order, Markman scheduling, claim construction orders, and any dispositive motion outcomes).

Key docket milestones that must be verified

  • Complaint and amended complaint filing dates
  • Answer and any Rule 12 motions
  • Markman schedule and claim construction order(s)
  • Summary judgment rulings (infringement, invalidity, indefiniteness, enablement, written description)
  • Trial date and any stay (PTAB, ITC, related cases)
  • Settlement or voluntary dismissal indicators (stipulations, consent orders)

No such entries are available here in a citable way.


How strong is MR Technologies’ patent estate in 8:22-cv-01599 based on the public record?

Direct answer: Strength cannot be quantified because the asserted patents, expiration positions, and prior art context are not identifiable from the available information.

What would determine strength in a Western Digital infringement case

For a defensible strength assessment, the analysis would require:

  • The asserted claims (independent/dependent claim counts and claim limitations)
  • Claim construction outcomes
  • Relevant prior art disclosures and obviousness combinations
  • Commercial nexus (accused products and sales/usage evidence)
  • Validity risks (Section 101 subject matter, Section 102 novelty, Section 103 obviousness, Section 112 written description/enablement)

Those inputs are not present.


What claims does Western Digital argue are not infringed in 8:22-cv-01599?

Direct answer: Infringement positions cannot be summarized without knowing the accused products, claim charts, and Western Digital’s noninfringement defenses.

Noninfringement arguments that are commonly case-dispositive

  • Claim limitation absence (device architecture, signal processing, material layer properties)
  • Failure to meet performance thresholds or functional results
  • Indefiniteness based on ambiguous structural terms
  • Prosecution history disclaimer impacting claim scope

No defense content is available here.


What invalidity defenses are raised (anticipation, obviousness, indefiniteness, §101) in 8:22-cv-01599?

Direct answer: Invalidity theories cannot be enumerated without the invalidity contentions and any motion papers.

What to check for in the record

  • Prior art references and mapping to each limitation
  • Whether the case includes PTAB challenges to the same patents
  • Whether indefiniteness attacks target key structural or functional claim terms
  • Whether §101 arguments target method claims vs apparatus/system claims

No such mapping is available.


Are there PTAB inter partes review or post-grant proceedings tied to 8:22-cv-01599?

Direct answer: The presence or absence of PTAB proceedings cannot be stated.

Why PTAB linkage matters

If PTAB petitions exist, they can affect:

  • Claim construction scope (via estoppel)
  • Settlement leverage
  • Timing for trial and dispositive motion posture

No PTAB data is available here.


What is the Orange Book status of the asserted patents in this case?

Direct answer: This litigation does not provide enough information to determine any relationship to an FDA-approved drug with an Orange Book entry.


What generic or biosimilar entry risks exist for Western Digital products under 8:22-cv-01599?

Direct answer: “Generic” and “biosimilar” market-exclusivity concepts do not apply to this case caption in a verifiable way without the accused product category and any FDA regulatory linkage.


How does MR Technologies’ litigation strategy compare with other MR patent plaintiffs against storage or hardware OEMs?

Direct answer: A defensible comparison cannot be made without knowing:

  • The asserted technology domain
  • The venue pattern (E.D. Texas, D. Delaware, ITC, etc.)
  • The typical claim construction outcomes
  • The settlement/dismissal patterns

Those elements require data not available in this feed.


Key Takeaways

  • A claim-level litigation summary for MR Technologies, GmbH v. Western Digital Technologies, Inc. (8:22-cv-01599) cannot be produced accurately from available information.
  • A complete analysis requires docket-specific entries (asserted patents, claim construction, dispositive rulings, and trial/settlement outcome) that are not provided here.
  • No reliable statements can be made about infringement defenses, invalidity grounds, PTAB linkage, or litigation timeline.

FAQs

  1. What is the filing date and division for MR Technologies, GmbH v. Western Digital Technologies (8:22-cv-01599)?
  2. Which court orders and hearings occurred in 8:22-cv-01599 (Markman, scheduling, dispositive motions)?
  3. What products are accused in 8:22-cv-01599, and which claim limitations does Western Digital dispute?
  4. Have any asserted patents been challenged at the PTAB in connection with 8:22-cv-01599?
  5. Did the case end in settlement, dismissal, or judgment, and what was the outcome?

References

  1. Case caption: MR Technologies, GmbH v. Western Digital Technologies, Inc., No. 8:22-cv-01599.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.